davalintide: a synthetic amylin-mimetic peptide with appetitie suppresant activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71587842 |
| MeSH ID | M0551283 |
| Synonym |
|---|
| 863919-85-1 |
| l-tyrosinamide, l-lysyl-l-cysteinyl-l-asparaginyl-l-threonyl-l-alanyl-l-threonyl-l-cysteinyl-l-valyl-l-leucylglycyl-l-arginyl-l-leucyl-l-seryl-l-glutaminyl-l-alpha-glutamyl-l-leucyl-l-histidyl-l-arginyl-l-leucyl-l-glutaminyl-l-threonyl-l-tyrosyl-l-proly |
| ac 2307 |
| 668u999f9t , |
| davalintide |
| unii-668u999f9t |
| davalintide [usan:inn] |
| l-lysyl-des-2-l-serine-(4-l-threonine(lt),5-l-alanine(sa),11-l-arginine(kr),18-l-arginine(kr),30-l-asparagine(gn),32-l-tyrosine(py))calcitonin-1 oncorhynchus keta (chum salmon), calcitonin-1 precursor-(83-114)-peptidamide |
| dacra |
| gtpl10684 |
Davalintide is a second-generation amylinomimetic peptide. It has enhanced pharmacological properties over ratAmylin to reduce food intake in preclinical models.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Davalintide is a second-generation amylinomimetic peptide possessing enhanced pharmacological properties over rat amylin to reduce food intake in preclinical models. " | ( Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Athanacio, JR; Jodka, CM; Lu, MG; Mack, CM; Parkes, DG; Reynolds, JM; Smith, PA; Wilson, JK; Xu, K, 2011) | 2.05 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compound 10's terminal half-life of ~27 h should translate favorably to weekly dosing in humans." | ( Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics. Forood, B; Ghosh, SS; Griffin, P; Jodka, CM; Neravetla, S; Parkes, DG; Sun, C; Trevaskis, JL; Wang, Y; Xu, K, 2013) | 0.39 |
| "0 μg/kg) were compared with similar davalintide doses in high-fat diet (HFD)-fed rats receiving subcutaneous dosing once daily for 62 days." | ( KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Andreassen, KV; Christensen, JM; Gydesen, S; Henriksen, K; Hjuler, ST; Karsdal, MA, 2016) | 0.94 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.93) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||